A gene therapy company changing lives with every genetic advancement
At Asklepios BioPharmaceutical (AskBio), we are making history with every clinical advancement and aspire to turn hope into cures by unraveling new possibilities for genetic medicine. We are headquartered in Research Triangle Park, North Carolina, a thriving biotechnology hub with nearly 600 life science companies, and have additional research and development facilities in Edinburgh, Scotland, and Paris, France, and gene therapy manufacturing in San Sebastian, Spain.
Started in 2001, we are on a never-ending quest to advance genetic technology and life-saving gene therapy. We are singularly focused on a goal to erase genetic disease. It is an audacious goal that will not be accomplished by us alone, but it is one to which we have already made significant contributions.
Almost 40 years ago, AskBio’s scientific co-founder, Jude Samulski, PhD, was the first to demonstrate that adeno-associated virus (AAV) could be cloned for therapeutic purposes. His groundbreaking research propelled the most exciting field in medical research today. His work inspires our world-leading gene therapy platform that is bringing new therapeutics to market and resulting in new methods for lowering the cost of delivery.
Meeting the challenges of genetic medicine
Our scientific and clinical teams are solving some of the most complex problems facing biotechnology and gene therapy.
- Extensive global research collaborations
- Integrated gene therapy platform includes a high-yield cell line, an expansive capsid library, and synthetic promoters and DNA
- New delivery methods to accelerate and lower the cost of producing curative therapeutics
- Over 350,000 square feet of lab, research and scaled in-house AAV manufacturing
- Foundational scientific expertise resulting in a portfolio of 500+ patents for gene therapy development, clinical processes and manufacturing
- Rapidly expanding pipeline of potentially curative treatments
Our clinical pipeline covers a broad range of genetic diseases targeting central nervous system, muscle and heart tissues. We have a number of research initiatives taking place to expand our pipeline that we believe will impact the future of other important therapeutics.
Our technology and AAV therapeutic assets have been acquired or licensed by leading biopharmaceutical companies such as Pfizer, Takeda, and Novartis. This validates our gene therapy development leadership and is even more significant considering that the first two gene therapies approved by the FDA are based on the research of our founders and AskBio’s current technology.
We welcome hearing from you if you would like more information about AskBio.
Jude Samulski story
Jude Samulski was a graduate student at the University of Florida when he discovered the possibilities of the AAV virus.
The AskBio leadership team has some of the best minds in science, clinical development and commercialization.
Board of directors
AskBio’s board of directors plays an integral role in our success as they help guide our world-class, leading gene therapy company.